Research and Development Investment: Lantheus Holdings, Inc. vs TG Therapeutics, Inc.

Biotech Giants' R&D Race: A Decade of Strategic Investments

__timestampLantheus Holdings, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20141367300031354781
Thursday, January 1, 20151435800043445817
Friday, January 1, 20161220300066489820
Sunday, January 1, 20171812500096886134
Monday, January 1, 201817071000153793000
Tuesday, January 1, 201920018000148369000
Wednesday, January 1, 202032788000151934000
Friday, January 1, 202144966000198532000
Saturday, January 1, 2022311681000112128000
Sunday, January 1, 20237770700076192000
Loading chart...

Data in motion

A Decade of Innovation: Lantheus Holdings, Inc. vs TG Therapeutics, Inc.

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Lantheus Holdings, Inc. and TG Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, TG Therapeutics consistently outpaced Lantheus in R&D spending, peaking in 2021 with a staggering 198% increase from 2014. However, in 2022, Lantheus made a significant leap, increasing its R&D investment by over 900% compared to its 2014 figures, surpassing TG Therapeutics for the first time. This shift underscores Lantheus's commitment to innovation and adaptation in a competitive market. As we look to the future, these investments will likely shape the trajectory of both companies, influencing their market positions and the broader biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025